Objective: Traditional prognostic factors have proved insufficient to account for heterogeneity in the clinical behavior of chronic lymphocytic leukemia (CLL). -1 () is a circadian clock gene essential in maintaining the circadian rhythm and regulating cell proliferation. We evaluated gene expression in CLL and addressed its putative role as a prognostic indicator for the clinical course of CLL.
Materials And Methods: A total of 100 CLL patients at diagnosis were studied for gene expression by real-time reverse-transcription polymerase chain reaction and were followed for assessment of time to first treatment (TFT).
Results: was expressed in 94% of the CLL patients at diagnosis. The median relative gene expression level (0.006) stratified patients into high and low expression groups. Forty of 100 (40%) CLL patients showed high , 54/100 (54%) showed low , and 6/100 (6%) had undetectable gene expression. High gene expression was concordant with CD38, Zap-70, and double CD38Zap-70 expression; unfavorable/intermediate cytogenetics; unmutated gene; and diffuse marrow infiltration. The high gene expression patient group exhibited shorter TFT than the patients with low gene expression. A Cox proportional hazard regression model identified gene expression to be independently predictive for TFT.
Conclusion: is differentially expressed among CLL patients, stratifying them into low-risk and high-risk groups. gene expression could constitute a reliable prognostic indicator for CLL progression, complementing the role of standard well-established prognostic factors. gene expression could be employed as a prognostic indicator for disease progression during the initial prognostic work-up and follow-up for CLL patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110451 | PMC |
http://dx.doi.org/10.4274/tjh.2017.0169 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!